A sedar

Canadian Daytrading

2016.12.31 01:16 Vigil123 Canadian Daytrading

Share stock tickers, analysis, information and news release likely to move a stock for day trading / swing trading.

2014.10.25 16:02 vekula Canadian Investor

Canadians Interested in investing and looking at opportunity in the market besides being a potato. Discussion would be geared around any investment opportunities a Canadian has access to. Questions regarding individual companies, ETFs, Tax implications, Index Investing, and more...

2015.11.01 13:53 kreveterrr Canopy Growth Corp

CanopyGrowthCorp for discussion of the world's largest marijuana producer.

2020.11.25 17:24 TraderBTS MMED Bought Deal November 25th

So, this bought deal was announced on the company's website but was not, still isn't posted on the SEDAR website. Isn't this illegal and implies insider dealing?
submitted by TraderBTS to MindMedInvestorsClub [link] [comments]

2020.11.25 17:20 TraderBTS MMED Bought Deal November 25th

So this bought deal was announced on the company's website but was not, still isn't posted on the SEDAR website. Isn't this illegal and implies insider dealing?
submitted by TraderBTS to shroomstocks [link] [comments]

2020.11.24 12:58 weedislifeman Quinsam Capital Corporation Q3/2020

Quinsam Capital Corporation Q3/2020
Toronto, Ontario, November 23, 2020 – Quinsam Capital Corporation (CSE:QCA) (“Quinsam” or the “Company”) wishes to announce its Q3/2020 results, with net income of $0.8 million ($0.01 per share basic, $0.01 fully diluted) versus a net loss of $5.2 million ($0.05 per share basic, $0.04 fully diluted) in Q3/2019. Investors can access the company’s full financial statements on sedar.com.“At September 30, 2020, we had net assets of approximately $0.30 per share” said Roger Dent, CEO of Quinsam. “Our growth in NAV per share exceeded EPS due to the favourable impact of our ongoing normal course issuer bid purchases.”Market conditions stabilized in Q3 and this helped the valuations of some of our publicly-traded investments. This has also improved the prospects for our private company and debt investments, although our carrying values were not generally impacted.Overall, our portfolio of cannabis investments had a positive if muted performance. In Quinsam’s non-cannabis portfolio, we saw a strong performance by Newlox Gold, which moved from $0.055 at the end of Q2 to $0.115 at the end of Q3 and to a recent trading level of $0.16. Quinsam’s private e-sports betting investment, PMML, completed a $3 million investment round at a premium of approximately 50% to our previous carrying value, which was reflected in our Q3 results. PMML currently plans a public listing in early 2021.One of Quinsam’s cannabis companies completed a liquidity event in Q3, Molecule Holdings. This was not a large investment for us and it did not have a significant impact on the quarter. Several more of Quinsam’s investee companies have announced 2020 liquidity plans including Eden Empire, Ikanik Farms and Embark, all of which have announced RTO transactions and are expected to trade in the near term.In recent months we have made a number of smaller follow-on investments in some of our existing issuers including Pharmadrug debentures, Nutritional High mortgage debentures and additional loans to Budd Hutt. We also recently exercised one tranche of our Agri Force warrants. We sold our free trading shares in CB2 Insights and replaced the holding at a lower cost with units of CB2’s $0.15 September new issue. We participated in a unit new issue by Lexagene. We sold the Lexagene shares comprising part of the unit for nearly all our total unit cost and retain the warrants at a negligible residual cash investment. We acquired a small position in Nexe Innovations, a manufacturer of environmentally-friendly Keurig pods, which is expected to start trading in the near term. We have also made an investment in Peak Health, a Toronto-based medical clinic company where we expect to see a liquidity event in 2021.Issuer Bid UpdateQuinsam announced a normal course issuer bid to purchase up to 5,446,952 of its common shares (the “Bid”) in August 2020. The Company commenced the Bid because it believes that the current market price of its common shares may not fully reflect the underlying value of the Company’s business and future prospects. The Company believes that the repurchase of its common shares for cancellation is in the best interests of its shareholders because the Bid will increase the respective proportionate shareholdings and equity interests of all remaining shareholders. The Company commenced the Bid on August 28, 2020 and it will terminate on August 27, 2021, or on an earlier date in the event that the number of common shares sought in the Bid has been repurchased. The Company reserves the right to terminate the Bid earlier if it feels that it is appropriate to do so. All common shares will be purchased on the open market through the facilities of the Canadian Securities Exchange (“CSE”), and payment for the common shares will be made in accordance with CSE policies. The price paid for the common shares will be the prevailing market price at the time of purchase. Purchases may be suspended at any time, and no purchases will be made other than by means of open market transactions during the term of the Bid. The Company has engaged M Partners to act as the broker through which the Bid will be conducted.In the quarter ending September 30, 2020, Quinsam repurchased and cancelled 2,250,000 shares pursuant to the Bid, bringing total repurchases pursuant to the Bid since August 28, 2020 to 2,250,000 shares. The shares were purchased at a large discount to NAV and the repurchases had a positive impact on NAV per share for remaining shareholders.
Submitted November 24, 2020 at 11:23AM
submitted by weedislifeman to weedstocksreddit [link] [comments]

2020.11.22 17:33 Svastyckh Los médicos holandeses podrán sedar "en secreto" a los pacientes con demencia antes de practicarles la eutanasia acordada - Usaran eso como arma para deshacerse de sus enemigos politicos y los que estan bajo sus intereses

Los médicos holandeses podrán sedar submitted by Svastyckh to ActualidadMundial [link] [comments]

2020.11.20 16:31 Technical_Joker MindMed MD&A Basic Projects

Before reading please note that I did not write any of this - everything below is taken from the most recent MD&A . Just wanted to make it easily accessible for anyone here. This isn't the complete MD&A - the complete MD&A can be found on SEDAR.
MindMed is a neuro-pharmaceutical drug development platform advancing medicines based on psychedelic substances through rigorous science and clinical trials. MindMed’s mission is to discover, develop and deploy psychedelic inspired medicines and experiential therapies that alleviate suffering and improve health. Through our unique drug development platform, we seek to prove the safety and efficacy of psychedelic-based substances as disruptive technologies and solutions for a continuum of mental illnesses and high unmet medical needs.
MindMed operates a distributed platform with activities in Switzerland, Australia, the United States and Canada.
MindMed utilizes a Discover, Develop and Deploy process in order to advance psychedelic inspired medicines and experiential therapies. We define Discover as being the non-clinical, pre-clinical, and human clinical trials of psychedelic substances led by academic clinical investigators, discovery of new chemical entities and formulations based on psychedelics, and the advancement of research and development on technologies that seek to improve the safety and efficacy of psychedelic inspired medicines and experiential therapies. We define Develop as being commercial drug development programs that are being translated from the Discover mandates and advanced as commercial, company-sponsored drug development programs through clinical registration trials. We define Deploy as being our commercialization mandates that will aim to partner with insurers, technology companies and care providers to scale access to our potentially approved medicines to patients in need. Each term is used throughout this Prospectus.
MindMed’s business is premised on a growing body of research that psychedelics can be a new way to treat a myriad of mental health problems. Regardless of the treatment, the board of directors and management of the Corporation intend for MindMed’s approach to always be the same – the psychedelic inspired medicines and experiential therapies that it develops will be commercialized, if they can be, as regulated medicines. This entails conducting clinical trials utilizing research scientists with extensive psychedelics backgrounds, using experienced clinical drug development teams, the producing and supplying of drugs according to current Good Manufacturing Practices, and conducting all trials and development under the supervision and guidance of the US FDA and ex-US regulatory authorities.
In the Discover projects, the Corporation conducts R&D in collaboration with the UHB Liechti Lab on various psychedelics and new therapeutic potentials based on a multi-year, exclusive collaboration agreement with the UHB Liechti Lab signed on April 1, 2020. The agreement first covered LSD, but has since been expanded to now incorporate other compounds and psychedelic substances such as MDMA, DMT, LSD, MDMA-LSD and psilocybin. These R&D clinical trials, intellectual property and technologies may ultimately be translated to commercial development programs. MindMed is continually evaluating the acquisition of agreements and studies focusing on the medical benefits of other psychedelic substances and new chemical entities similar to known psychedelic substances to advance its R&D efforts.
The MindMed commercial development pipeline consists of agreements and studies relating to 18-MC and LSD. The Corporation’s immediate commercial development priorities are to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine, conduct clinical trials of LSD micro-dosing for adult ADHD, and to conduct clinical trials of LSD experiential therapy for anxiety disorders.
Our strategy is currently focused on the discovery and development of psychedelic substances, but we will ultimately seek to commercialize and deploy our psychedelic inspired medicines and experiential therapies in the future to patients in need. As a result, the Corporation has recently entered into a funding arrangement with NYU Langone Health and the NYU Grossman School Of Medicine (“NYU Langone Health”) to establish the NYU Langone Health Psychedelic Medicine Clinical Training Program (“NYU Langone Training Program”) to help the Corporation understand and prepare for the future Deploy phase of its business plan.
Addiction Program - Develop
The Addiction Program is currently broken into two clinical trial pathways. The first pathway is focused on opioid withdrawal treatment, in respect of which the Corporation completed a Phase 1 trial. The Corporation is now undertaking a Phase 1b trial, with the first patients already enrolled for testing, that will provide additional safety and dose ranging data. Depending on the results of the Phase 1b trial, the Corporation expects to initiate a Phase 2 trial in 2020 or early 2021 intended to evaluate 18-MC’s effectiveness for withdrawal treatment and to determine the shortterm adverse effects and risks associated with the treatment. The second pathway focuses on use disorder. A Phase 3 clinical trial for opioid withdrawal or opioid use disorder is projected to commence at the very earliest at the end of 2021 or in 2022, subject to statistically significant results and findings from the Phase 2 clinical trials. Findings from the Phase 2 trials could greatly impact timelines and future capital requirements for the Addiction Program. In addition, the Corporation may need to conduct additional Phase 2 trials or additional studies to progress the Addiction Program, which may impact timelines and required capital. The above also assumes that the Corporation intends to apply for Breakthrough Therapy Designation from the FDA for the Addiction Program, which may or may not positively impact the projected timelines referred to above if granted by the FDA. The Corporation’s budgeted Phase 1b costs for the trials are currently anticipated to be between US$4.3 million and US$6 million, the results of which will inform future budgets of Phase 2 trials and future milestones.
Project Lucy - Develop
As part of MindMed’s decision to add an experiential therapy for anxiety disorders to its clinical development pipeline, MindMed has established Project Lucy, in respect of which a briefing package is being prepared for an IND with the FDA for the treatment of anxiety disorders with LSD. MindMed is assembling and using data from its data acquisition from the University Hospital Basel as part of its briefing package to the FDA. The anticipated timeline for opening the IND is the second half of 2021. A pre-IND meeting has been scheduled with the FDA in December 2020. As a result of the Corporation’s data acquisition from the University Hospital Basel, MindMed received the data and worldwide rights to an ongoing Phase 2 trial in respect of experiential LSD for anxiety administered by Professor Dr. Liechti and a psychedelic therapy expert, Dr. Peter Gasser. Dr. Gasser was appointed as the Clinical Advisor for Project Lucy in August, 2020.
The data and knowhow will help build MindMed’s understanding of LSD’s uses for anxiety disorders and its platform for LSD as a potential prescription medication for serious mental health conditions. The first read out from this Phase 2 experiential LSD anxiety trial is planned for the first quarter of 2021.
In addition to using LSD for anxiety, MindMed is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at the UHB Liechti Lab. Cluster headaches are a relatively uncommon primary headache disorder that is one of the trigeminal autonomic cephalgias; they are considered to be among the most severe forms of pain. The Phase 2 trial began recruiting patients in early January 2020 and has commenced treating patients with experiential LSD. Professor Dr. Liechti is serving as principal investigator of the clinical trial. The UHB Liechti Lab and MindMed intend to learn how they can make the administration of LSD more targeted for cluster headache patients through this Phase 2 trial and future clinical trials. As part of the collaboration with the UHB Liechti Lab, MindMed gained exclusive, global use to all data and intellectual property generated in this Phase 2 trial of LSD for cluster headaches.
Microdose LSD Program - Develop
A Phase 2a proof of concept trial for the Microdose LSD Program is, as of the date of this Prospectus, advancing through the necessary regulatory filings in the Netherlands and Switzerland. The Corporation has appointed two principal investigators and signed clinical trial agreements with the University Hospital Basel and Maastricht University. After MindMed’s clinical team assesses the results from the Phase 2a proof of concept clinical trial, the Corporation will determine the best future strategy for additional clinical trials based on these findings and future milestones for the project. To the knowledge of the Corporation and management, this is the first ever Phase 2a clinical trial of micro-dosing LSD for commercial drug development. It is extremely complex to estimate what future trials and studies will be required until a proof of concept of the technology has been established in the current trial being prepared by the Corporation. At such time, the Corporation will be in a better position to anticipate the needed capital to advance the Microdose LSD Program. The Corporation’s budgeted Phase 2a costs for the proof of concept trial are currently anticipated to be between US$3 million and US$4 million, the results of which will inform future budgets of Phase 2 trials; future milestones and the trial are anticipated to run over two years in 2021 and 2022.
MDMA & DMT R&D - UHB - Discover
MindMed recently added the psychedelic compound MDMA to its R&D pipeline, with research being led by Professor Dr. Liechti. After starting the UHB Liechti Lab, over the past ten years Professor Dr. Liechti has led multiple clinical trials of the safety profile and how MDMA interacts with the human body. The cumulative data from the work done in the UHB Liechti Lab will enable MindMed to design clinical trials and form a strategy for MDMA as part of its portfolio.
MindMed has committed to fund future R&D of new psychedelic therapies being pursued by the UHB Liechti Lab with the intention to create next-generation psychedelic inspired medicines that incorporate MDMA as a component of these therapies. The UHB Liechti Lab and MindMed plan to explore combination treatments of LSD and MDMA to optimize the subjective effect profiles and potentially join the benefits of both psychedelics in various treatment paradigms. A combined MDMA LSD randomized placebo controlled Phase 1 trial is planned to start at the end of 2020.
Concurrently, MindMed will pursue N,N-Dimethyltryptamine (DMT), the principally active ingredient in ayahuasca. MindMed is providing startup funding for a Phase 1 clinical trial testing various intravenous dosing regimens of DMT, expected to begin at the end of 2020. DMT is a naturally occurring psychedelic substance that causes a rapid onset and offset of action compared to similar psychedelic substances such as psilocybin or LSD. When administered as an ayahuasca brew, natural substances are mixed with DMT to prolong its experiential effects and slow the metabolism in the human body. Through this Phase 1 clinical trial, MindMed and the UHB Liechti Lab are exploring how DMT can achieve experiential effects similar to ayahuasca by testing a more controlled intravenous dosing method.
DMT is rapidly metabolized as it enters the body if taken orally and therefore it has a very short duration of action. In contrast, through a continuous intravenous perfusion application the effect of DMT is longer and can be stopped rapidly. In order to potentially induce a stable DMT experience lasting 1-2 hours, various intravenous dosing regimens including a starting dose and then a maintenance dose will be evaluated in the Phase 1 clinical trial. This intravenous administration may also allow therapists to induce and to end an experiential state safely and more quickly, as required.
There is non-clinical, anecdotal evidence which suggests DMT and ayahuasca’s experiential effects are powerful healing tools for addiction disorders. The human safety data and associated knowhow gathered in this Phase 1 clinical trial will better enable MindMed’s clinical team to design future potential commercial drug development programs based on DMT sessions. Currently, no study has validly determined the elimination half-life of DMT and other pharmacokinetic parameters and there is limited known data on dosing regimens of pure DMT. This Phase 1 double blind placebo controlled 5-period crossover design study will provide a well-controlled study setting to illuminate these shortcomings in the current clinical understanding of DMT and pave the way for future Phase 2a proof of concept efficacy studies in various indications.
Neutralizer Technology - UHB - Discover
In collaboration with the UHB Liechti Lab, MindMed filed a patent application in the United States (preserving all worldwide rights) for a neutralizer technology intended to shorten and stop the hallucinogenic effects of using LSD during a therapy session. This discovery, when further developed, may act as the ‘off-switch’ to certain hallucinogenic effects. The invention may help reduce the acute effects of a psychedelic drug and help shorten the hallucinogenic effects when required by a patient or medical professional. One of the many fears and stigmas associated with psychedelics are rare occurrences of negative hallucinogenic effects, or ‘bad trips’. MindMed is seeking to equip therapists and other medical professionals with the resources and technology to better control the effects of dosing LSD in a clinical setting to improve the patient experience and outcomes. This would pave the way for greater therapeutic applications of LSD and shorter-acting psychedelic therapy treatments. MindMed believes this technology, when further developed, may one day be marketed as an added feature to shorten or stop a therapy session if the patient is not comfortable.
Personalized Medicine Technology - UHB - Discover
MindMed, in collaboration with UHB Liechti Lab, is also in the process of researching and developing technologies and analytics that seek to personalize psychedelic therapy experiences for a specific patient. The technology aims to optimize the dosing of MDMA, LSD and other psychedelics based on a patient’s profile. A considerable problem for doctors, clinical researchers, and therapists is to understand and predict optimal doses of psychedelic inspired medicines for patients. Through its clinical research, the UHB Liechti Lab has identified novel ways to predict and optimize the amount of a psychedelic dose and dosing regimen for therapy. To assemble a patient’s personalized dosing regimen and therapy session, MindMed and the UHB Liechti Lab’s analytics method aggregates multiple data and criteria of patients in a pre-dose screening and analysis process. MindMed intends to apply this personalized medicine approach to psychedelic assisted therapies for patients suffering from mental health and addiction issues.
Additionally, two separate patent applications have been filed covering MDMA dose optimization and LSD dose response. MindMed has received the exclusive rights from the University Hospital Basel to commercialize the outcome of these patent applications on a global basis.
Clinical Training - NYU - Deploy
On October 6, 2020, the Corporation announced a commitment of US$5 million over a five-year period to found and launch a clinical training program focused on psychedelic assisted therapies and psychedelic inspired medicines at NYU Langone Health, one of the United States’ premier academic medical centers. The NYU Langone Training Program is the first step in a larger initiative to establish a Center for Psychedelic Medicine at NYU Langone Health. NYU Langone Health will have full and free discretion in using the funds for the development and conduct of the training program and operations of the Center for Psychedelic Medicine. The launch of the Center for Psychedelic Medicine at NYU Langone Health is still subject to additional funding from other partners and parties. It is not anticipated that the Corporation will generate future revenue from this project.
submitted by Technical_Joker to MindMedInvestorsClub [link] [comments]

2020.11.18 15:00 AutoModerator Happy Cakeday, r/scrapbooking! Today you're 9

Let's look back at some memorable moments and interesting insights from last year.
Your top 10 posts:
submitted by AutoModerator to scrapbooking [link] [comments]

2020.11.16 16:02 Always2xDown NAK News Out - Compensatory Mitigation Plan for Alaska’s Pebble Project submitted to US Army Corps of Engineers

Added link , copy paste from my email I just received
Northern Dynasty: Compensatory Mitigation Plan for Alaska’s Pebble Project submitted to US Army Corps of Engineers
November 16, 2020 Vancouver – Northern Dynasty Minerals Ltd. (TSX: NDM; NYSE American: NAK) ("Northern Dynasty" or the "Company") announces that its 100%-owned US-based subsidiary Pebble Limited Partnership (the “Pebble Partnership”) has submitted a Compensatory Mitigation Plan (“CMP”) for the Pebble Project to the US Army Corps of Engineers (“USACE”) ahead of the 90-day deadline that expires on November 18, 2020.
Northern Dynasty and the Pebble Partnership believe the submitted CMP fully satisfies mitigation requirements for the proposed copper-gold-molybdenum-silver-rhenium mine in southwest Alaska.
Following publication of a positive Final Environmental Impact Statement (“EIS”) in July 2020, the USACE published its mitigation requirements for Pebble on August 20, 2020 and provided the Pebble Partnership with 90 days to submit a CMP to address them. Filing an approved CMP for the project is a necessary prerequisite to receiving a federal Record of Decision (“ROD”).
“The ‘in-kind’ and ‘in-watershed’ requirement for mitigation the USACE established for Pebble clearly sets a high bar for offsetting project effects on wetlands and other aquatic features, but it’s a challenge we have embraced and believe we can achieve,” said Ron Thiessen, Northern Dynasty President & CEO.
“Based on the findings of the Final EIS, we already know Pebble can operate safely and reliably, while fully protecting the water, fish and wildlife resources of Bristol Bay. Meeting the USACE’s challenging mitigation requirements provides even greater evidence that Pebble can and will co-exist with commercial, subsistence and sport fisheries in southwest Alaska.”
In addition to meeting the rigorous environmental standards enforced in the Clean Water Act and other US federal legislation, Thiessen said the Final EIS for Pebble indicates the project will make important, positive socioeconomic contributions to the region, the state and the nation.
“Pebble will also deliver the critical and strategic minerals the United States requires for its economic and military security,” he said, “while helping facilitate the transition to a ‘lower carbon future.’”
Thiessen said Pebble Partnership technical/permitting staff and expert, third-party consultants in Alaska have prepared a high-quality mitigation plan to fully satisfy the lead federal agencies’ requirements – including undertaking extensive field investigations this summer and fall. He cautioned Pebble won’t be releasing any details about the CMP until it is accepted by the USACE and posted to its website.
“We have an experienced team in Alaska that has identified both the means and mechanism to meet the ‘in-kind’ and ‘in watershed’ mitigation requirements, and complete a CMP that we believe will be acceptable to the USACE in form and content,” he said. “Until this work is completed to the Corps’ full satisfaction, we won’t be discussing the details of our plan.”
There is no statutory timeline for the USACE’s review of the Pebble CMP. Northern Dynasty’s current expectation is that its sufficiency will be confirmed prior to or concurrent with issuance of a final Record of Decision.
About Northern Dynasty Minerals Ltd.
Northern Dynasty is a mineral exploration and development company based in Vancouver, Canada. Northern Dynasty's principal asset, owned through its wholly owned Alaska-based U.S. subsidiary, Pebble Limited Partnership (“PLP”), is a 100% interest in a contiguous block of 2,402 mineral claims in southwest Alaska, including the Pebble deposit. PLP is the proponent of the Pebble Project, an initiative to develop one of the world's most important mineral resources.
For further details on Northern Dynasty and the Pebble Project, please visit the Company's website at www.northerndynastyminerals.com or contact Investor services at (604) 684-6365 or within North America at 1-800-667-2114. Review Canadian public filings at www.sedar.com and US public filings at www.sec.gov.
Ronald W. Thiessen President & CEO
US Media Contact: Dan Gagnier Gagnier Communications (646) 569-5897
submitted by Always2xDown to pennystocks [link] [comments]

2020.11.12 22:45 Neat_Ad_9183 How to access technical reports from major companies on the ASX?

Hi everyone! This might belong somewhere else (maybe mining or geology) but I thought I'd try here first since I am doing research to prepare for a job interview. Please advise if this should go somewhere else and I'll be sure to move this.
I'm trying to learn more about a deposit owned by an ASX-listed company, and so am looking for a JORC compliant technical report to read what the mine geos have come up with for the deposit's geology. For TSX-listed companies, even majors, this process is pretty simple: just look up who built the mine and find a 43-101 Feasibility Study (or later 43-101 technical report, like a resource update) via sedar, and you have an entire geology section to read. The work might not be particularly groundbreaking, but it's generally a great starting point for finding any relevant academic studies that have been done and is, in my experience, the fast-lane to learning about a deposit's geology. It certainly beats just reading the company's website.
Unfortunately I'm struggling to find a similar work-flow for this ASX company's deposit. Any suggestions? The asx.com.au site has been pretty useless so far, yielding only PowerPoints or very brief announcements of various drill results.
submitted by Neat_Ad_9183 to geologycareers [link] [comments]

2020.10.31 08:33 davismiller676 Sedar Blinds Dubai, Abu Dhabi & UAE

Sedar window blinds in Dubai is stunning, flexible, purposeful and a relatively perfect window comfort in spite of what the home décor is. curler blinds now not most effective beautify or beautify the home indoors but additionally they furnish privateness. https://furnitureonline.ae/sedar-blinds/ Email :[[email protected]](mailto:[email protected]) Call Now : 056-600-9626
submitted by davismiller676 to u/davismiller676 [link] [comments]

2020.10.22 15:29 jubanis819 Is SEDAR all we have?

Basically the title. For US equities, the SEC website is great. Is the only Canadian alternative SEDAR?
I understand looks don’t matter, but I thought I got to a fake website the first time I visited SEDAR.
submitted by jubanis819 to CanadianInvestor [link] [comments]

2020.10.17 12:07 Majhul_101 France’s “Laïcité”, the Secular Fundamentalism at War with Multiculturalism

France’s “Laïcité”, the Secular Fundamentalism at War with Multiculturalism


France’s problem with multiculturalism is not a new phenomenon. Since the end of World War II, France has become one of the most ethnically diverse countries in Western Europe. The rapid growth of its multiculturalism started when France welcomed millions of immigrants mainly from its former colonies in North Africa, Sub-Saharan Africa, and South-East Asia to take part in its post-war economic recovery.
Unlike many of its Western counterparts like the United States, Canada, or Australia, France has implemented a “color-blind” approach in dealing with multiculturalism. It means that the French government does not institute policies that target a particular ethnic group or race, but instead, it institutes policies that target a specific geographic area or social cluster in which they tend to be ethnically-clustered. In 1978, France enacted a law that made it illegal to collect data on race or ethnicity. The law makes it difficult to assess the cultural composition of French society. Experts believe that visible minority is estimated to be 14% of the French population versus 20% in the United States and 22% in Canada.
While France, officially, holds a color-blind stance with regards to its multicultural society, the truth of the matter is that its political leaders and citizens are not blind to the fact that race and ethnicity do matter. Anyone who says otherwise is not believable.
Given the color-blind approach and the lack of data on race or ethnicity, it is difficult to accurately comprehend how effective France has been in assessing and combatting racism. In May 2020, a French government spokesman of Senegalese origin, Sibeth Ndiaye, surprised the French government when she made the call to legalize ethnic statistics. Ndiaye pointed out that the absence of statistics makes it difficult for people to assess how prevalent racism is in France. The response from the economy minister Bruno Le Maire was that the call did not align with France’s idea of universalism and that the concept of a French person does not consider his or her race, ethnicity, or religion. In his address of racism, the minister resorted to the condemnation of discrimination in any shape or form. While these statements are nice noble words, it does not tell us much on the prevalence of racism in France and the government effectiveness in combating racism. So, what is the real situation of racism in France?

1- Racism in France

In 1997, the Economist did a study on racism in France. They found that about 48% of French citizens consider themselves to be racists coming in second place after Belgium. Among those who feel racist, 35% would vote for the far-right, 35% would vote for the mainstream right, and 28% would vote for the left. The study also found that most French citizens believe that there are too many Arabs than Blacks and that there are too many Blacks than Jews.
Source: The Economist
Fast forward 2013, the Washington Post conducted another research survey in which they found that between 20% and 30% of French do not prefer people of another race as their neighbors. Another study by Pew research center in 2016 showed that only 26% of French believe that diversity makes their country a better place to live in contrast to 33% in the UK and 58% in the US. These percentages show that in comparison to the US, Canada, and the UK, France is the least tolerant. It also reveals that racial and ethnic diversity is seen more as a problem in France than in the US, the UK, Canada, and Australia.
Sources: Pew Research Center and Washington Post

2- Politicization of Arabs, Immigrants, and Islam

For decades, immigration has been a subject of political debate in France. French Arab which constitute the largest ethnic minority in France, have been the most stigmatized community and have been subject to political debates across the political spectrum. After 9/11, the stigmatization has rapidly gravitated toward Muslims (practitioners of Islam) which a large percentage is of Arab origin.
In early October 2020, French President Emmanuel Macron said that Islam is in crisis all over the world and plans to defend France’s secular values against what he termed as “Islamist radicalism”.
Source: Independent
The President’s comment is the latest example of mainstream politicians pandering to the far-right whose leader Marine Le Pen has seen her chances for winning the 2022 presidential election increased and is currently neck and neck with Macron.
Source: Politico
President Macron’s predecessors across the political spectrum have also used these tactics in the past:
Source: The Guardian
Source: The Guardian
Source: BBC
Source: France 24
According to Pew research, France has the largest Muslim community in Europe, representing 8.8% of the population. Yet, Muslims are often stigmatized in French political debates.
Source: Pew Research Center
To understand the place of Islam in France and how Arabs, Muslims, and Immigrants have been stigmatized across the political spectrum; it requires a need to understand three components: France’s secularism (laïcité), France’s history of colonialism and decolonization, and France’s history of anti-Semitism:

a- The French Revolution and the Birth of French Secularism (Laïcité)
For a very long time, France’s mainstream politics have had a deep suspicion of religion. A suspicion that dates back to the French Revolution. The French Revolution was a time in history when the population revolted against the Monarchy and the Church. For centuries, the Church had imposed its doctrine on society dictating every aspect of French lives. After the abolishment of the French monarchy, the new Republic began to marginalize the Catholic Church and all faiths from any participation and organization in public life. From that time onwards, the French State was born in direct opposition to the public display of religious organizations, religious faiths, religious symbols, and religious minorities.
In 1905, France enacted a law known as Laïcité, the French version of secularism. The 1905 law was founded on three main principles: the separation of Church and State, the supremacy of the State over religious institutions, and the neutrality of the State towards religion. In that regard, the French State guarantees the freedom of religion and the right of every French person to express one’s faith while respecting public order and institutions. The law does not recognize religious marriages and bans the display of religious symbols in public institutions.
This version of secularism explains in part the stigmatization of Muslims across the political spectrum.

b- France Colonial Past and Decolonization
In the 16th century, France established its first colony in Canada called New France at the time. A century later, France would colonize Africa and would take part in the slave trade of millions of Africans. The French colonization of North Africa (1830-1962) and the devastating Algerian Independence War (1954-1962) are factors that led to the presence of a major Arab community in France.
The Algerian war was France’s most violent decolonization. At the time, the French colony had the highest concentration of French citizens to the point it was given the status of “Department” (A French Province).
The Algerian War of Independence (1954-1962)
After World War II, the French economy was in tatters. The country was facing challenges to maintain its colonies worldwide. Soon after, France lost to its colony Vietnam which declared independence along with Laos and Cambodia, Algeria began declaring its independence. This event led France to wage a bitter colonial war against Algeria to maintain its largest colony. In 1962, France under Charles De Gaulle capitulated to Algeria which managed to gain its independence from France. Many French at the time saw De Gaulle's act as a betrayal to France and saw Algerians as the enemy to French integrity.
The Franco-Algerian war led to a massive emigration of Algerians to France, especially those who stood by France during the war. Immigration to France was not a new phenomenon at the time as privileged Algerians, Moroccans, Tunisians, Senegalese, Ivorians, and others (a majority of them being Muslims) had emigrated to France way before the conflict ever started. However, the war made it difficult for France to manage the massive wave of migration.
France's loss to Algeria would be a main factor that can explain the perception of native French on Arabs and Muslims. Initially, the negative public perception would focus on race and ethnicity targeting Arabs and Blacks, however as decades went by, especially after the 9/11 terrorist attack in New York, the focus would gradually gravitate towards religion targeting specifically Muslims and their faith (Islam). The figure below shows an increase in attacks against Muslims as they continue to face mistrust and violence in the secular country.
Source: The Huffington Post
c- Anti-Semitism
France has had a long history of anti-Semitism and discrimination against the Jews. The persecution began in the 12th Century after the Second Crusade with French clergyman giving frequent anti-Semitic sermons and discriminative taxes.
It was not after the French Revolution under Napoleon that citizenship was granted to the Jews. However, the celebration of the newfound freedom would be short-lived, as Napoleon would introduce anti-Jewish measures that annulled, reduced, or postponed all debts with Jews causing near ruin to the Jewish community. Restrictions were also placed on Jews to force them to assimilate.
In the late 19th century, an upsurge of anti-Semitism took place with newspapers circulating anti-Semitic rhetoric (i.e. The 1886 anti-Semetic Best Seller book of Edouard Drumont’s La France Juive). Nearly four decades later, at the beginning of World War I, Jewish immigration and anti-semitic campaigns were halted because of the need of the united front against Germany.
In 1894, the infamous Dreyfus case made shockwaves when Captain Alfred Dreyfus, a French Jew accused of espionage for the Germans, was sentenced for life. The government chose to suppress the evidence proving his innocence until Emile Zola and Jean Jaures brought to light the conspiracy. Dreyfus was released after serving ten years. The incident pushed France to create the 1905 Laïcité law.
France played a major role during the Second World War, when the Vichy government under Marshal Pétain collaborated with the Nazis by taking part in the deportation of 80,000 Jews to Nazi concentration camps, the execution of 15,000 Jews, and the creation of anti-Jewish discrimination laws. It was not until 2010 that France’s highest judicial body revealed that Nazi officials did not force the French to betray their fellow citizens and that anti-Semitic persecution was carried out willingly.
Source: France 24
For decades, the French government denied their involvement. It was not until 1995 that France under Jacques Chirac admitted France’s guilt and role in the persecution and mass deportations of Jews. With the long years of denial, it took also a long time for the French government to apprehend and try French war criminals (Jean Leguay in 1979, Paul Touvier in 1994, Maurice Papon in 1997). Marshal Pétain was only charged with treason not war crimes and had his sentence was commuted from death to life imprisonment by General De-Gaulles. Most convicts were given amnesty a few years later.
Thousands of French war criminals and collaborators would escape prosecution such as Jacques de Bernonville and Jacques Ploncard d'Assac whose son would join the National Front (now National Rally).
These criminals would also join the Organisation Armée Secrète or OAS (meaning Secret Armed Organisation) which carried out terrorist attacks, including bombings and assassinations, in an attempt to prevent Algeria's independence from French colonial rule.
The National Rally has a collection of Hitler and Nazi collaborator admirers whose far-right ideology is still part of the party’s DNA today.
France’s far-right ideology has a long history which dates back to the French revolution. Thirty years after World War II, the far-right movement would publicly resurface in 1972 under the leadership of Jean Marie Le Pen, the founder of the 'Front National' (National Front) party. The National Front under Le Pen was notorious for making anti-Semitic statements with a derogatory fixation on France’s Jewish population.
In the late 1970’s, a surge of racist and anti-Semitic attacks were carried against the Jewish community with monuments and cemeteries being desecrated and restaurants and shops being vandalized. Anti-Semitism would continue to be a problem in the late 1980s and 1990s. Many Jews were concerned of the rise of the National Front in politics which espouses anti-immigration and anti-Semitic views.
Jean-Marie Le Pen would also frame the narrative of the rejection of North African Muslim immigrants and “The Arab”. In 2011, her daughter Marine Le Pen would later re-brand the party to the name ‘Rassemblement National’ (National Rally) to soften the party’s past image on anti-Semitism. Only this time, her party would rally under the banner of “Laïcité” to spread Islamophobic attacks.
While many French citizens decry National Rally’s anti-Semitic discourse, many remain silent on anti-Islam or anti-Arab narratives by dismissing them as a right to free speech.
Source: Google
The rise of the far-right discourse in France has led to an increase in hate crimes against Jews and Muslims. According to the National Consultative Commission on Human Rights, CNCDH, a French governmental organization, the number of acts and threats of anti-Semitism (plotted in green) and racism and xenophobia (plotted in blue) has been on the rise.
Source: FiveThirtyEight
The upward trend of attacks also mirrors the rise of the National Rally which has been gaining popularity in key election battlegrounds. As a result, many Jews are pondering whether they should leave France. The trends show a growing exodus of Jews from France to Israel. France, home to the largest Jewish community in Europe, has seen the largest exodus of Jews for Israel in Western Europe.
Source: Vox

3- The Rise of France’s Far Right

For the past decades, the far-right has seen a gradual increase in voters support. Since 2011, the Party under the leadership of Marine Le Pen would see a stellar rise. Marine Le Pen’s anti-immigrant, anti-Europe, and anti-Islam stance was able to win her 10 million voters.
After decades of a toxic reputation linked with anti-Semitism and xenophobia, Marine Le Pen took the reins from her father and adopted a strategy of toning down their xenophobic and anti-Semitic image. The tactic worked in the party’s favor.
The stellar rise of Le Pen marks the growing normalization of far-right support in France. The far-right party under the banner of defending the principle of “Laïcité” (French version of secularism) and French identity, was able to rally a growing number of voters against Muslims and their faith. The slogan Le Pen concocted was ‘No to Islamism’. The National Rally wanted to paint the picture of Islam as an enemy fundamentalist ideology rather than a religion. This emphasis on Islamism started with Marine Le Pen in 2010 and has become the focus of her rhetoric.
The popularity of the far-right sets a dangerous precedent as mainstream political parties are gradually failing in halting the National Rally from taking the presidency. Across the spectrum, some politicians are starting to adopt some of Le Pen’s talking points. They are regularly using the identity card for political gains.
During the 2016 Presidential campaigns, Former Conservative candidate Francois Fillion called for a ban on the full-body Islamic burkini swimming suit. Former socialist prime minister, Manuel Valls, and former right-wing president Nicholas Sarkozy rallied behind the mayors’ ban on burkini swimming suits. Sarkozy made a promise to extend the ban on the hijab in schools to universities and restrict access to benefits for women who violate the ban, an action that has been detrimental to the emancipation and integration of young Muslim women. Today, Macron is trying to brandish his tough-on-Islam credentials in a populist political environment.
Source: Britannica
Source: AFP
Source: BBC
The stigmatization of minorities in political debates shows the ugliness of French politics. The French media has also been guilty of taking part in the narrative where inflammatory and racist statements have also been published.
Illustrations of Media Racism

4- French Secularism: The Root Cause of France’s Intolerance towards multi-culturalism

France is a country in crisis. The country’s secularism (French Laïcité) follows a doctrine that is fundamentalist and dogmatic, creating an environment of intolerance and lack of acceptance for other cultures. For a very long time, France has always wanted Assimilation and not Integration.
French secularism has been used as a political tool to target minorities and their faith. In the 1920s and 1930s, Polish and Italians immigrants were often targeted for practicing their Catholic faith and displaying their religious symbols in public.
In the aftermath of the Algerian war, the rejection of the North Africans was more of a rejection of their ethnicity rather than their religion. Over time, xenophobic attacks on French Arabs, Blacks, and other minorities eventually led to the 1983 March in protest against widespread racism, discrimination, and racial profiling and violence. For many young French of Arab descent (mostly of the second generation), the movement placed a greater emphasis on the acceptance of ethnic and cultural identity. The movement was advocacy for anti-racism, equality, political integration, social integration, and economic integration for minorities.
The 1983 March prompted President François Mitterrand to intervene in an attempt to diffuse the escalating movement. While the French authorities managed to diffuse the movement to the issue of race, it disregarded the demands for cultural recognition and socio-economic integration.
For decades, the government's lack of initiative to take minorities' demands seriously, compounded the frustrations of Franco-Arabs and other minorities. To add insult to injury, mainstream politicians have been politicizing their cultural identity and faith.

5- French Youth Radicalism: Decades of Marginalization in the Making

Years of constant stigmatization and exclusion of their cultural identity, ethnicity, and religion have driven French Arabs feeling very bitter towards their country France. But worse, it has pushed some French youths towards radicalism. While most French would attribute Islam as the cause of radicalism and violence, research has shown that the majority of Muslims staunchly oppose violence in the name of Islam (Pew Research Center).
The 1995 Paris metro bombings, the 2015 Charlie Hebdo attack, the 2015 Jewish Kosher Supermarket attack in Nice, and the 2015 mass shootings attacks on Stade de France, and other atrocious attacks are symptoms of France’s years of marginalization and intolerance towards its ethnic minorities giving birth to youth radicalism and terrorism. The increasing number of attacks paint a trouble picture.
According to a study on Terrorism, France holds the largest number of foreign fighters in western Europe. A 2016 report published by the International Centre for Counter-Terrorism (ICCT) estimates that over 900 French foreign fighters had traveled to Syria and Iraq between 2012 and 2015. Of this total, 75 percent had joined ISIS. The study paints a scary picture of a potential of 2000 radicalized French citizens that could be active in terrorist activities.
In contrast to France, the UK had about 750 foreign fighters who traveled abroad between 2011 and 2015. On the other hand, the US had far less with 200 US citizens and residents were convicted of terrorism-related activities between 2001 and 2013. About 250 Americans attempted to or successfully traveled to Syria and Iraq. While Canada had only 185 Canadian foreign fighters had traveled abroad.
The reason why France has more foreign fighters than its British and North-American counterparts is that the perceived better social, economic, and political integration of Muslims and other minorities in North American communities as compared to France.
Source: Pew Research Center
According to Pew Research Center, most Muslims in France feel very French however they feel that the native French don’t see them as French because of their ethnicity. The study also found that French Muslims are somewhat more likely than those in other Western countries to report that they have had experienced xenophobic and racist attacks with younger Muslims more likely to report a bad experience.
The Legatum Prosperity Index is an index that measures a country's level of individual freedom. The index ranks countries based on access to legal rights; freedom of speech and religion; and social tolerance, notably towards immigrants and ethnic minorities. The ranking shows that the UK (11th place), Canada (14th place), and the United States (18th place) are more tolerant than France ranking at 23rd place.
Part of the problem of France’s intolerance towards its minorities lies in its secondary education system. The French education system tends to glorify France's history while minimizing its legacy of colonialism and oppression. Such a set-up creates an uncomfortable feeling of identity for French minorities. Furthermore, contrary to North America, ethnic cultural studies are non-existent in France's secondary education. Such an education ecosystem creates a cultural rift between the majority culture and the minority multi-ethnic culture. A rift that the far-right has been able to exploit to its advantage.

6- France’s Secular Fundamentalism vs Secularism

Today, France’s version of secularism (Laïcité) is borderline 'secular fundamentalism'. This form of secularism is defined in the urban dictionary as:
The adherence to anti-religious ideology that militantly ridicules, mocks, scorns and satirizes the idea of the existence of a deity or deities and or religion, indifferent of feelings of bigotry intolerance hatred and persecution that adherents feel as a result.”
France’s secularism embodied by the spirit of Voltaire differ greatly from the Anglophones’ secularism embodied by the spirit of John Locke. The former advocates for State freedom from religious influence while the latter advocates for State liberal toleration towards religion. The two contrasting philosophies explain why multiculturalism tends to thrive in countries like the US, Canada, UK, New Zealand, or Australia as compared to France.
Laïcité comes from the Latin word ‘laicus’ which means “of the people”. It is a republican social pact that defines a place for religion in society. However, many francophones who look up to France, have a hard time reconciling the version of Laïcité that France is perpetuating. The kind of secularism that French politicians and the public have been using to justify intolerance and exclusion. True Laïcité should not be used to justify xenophobic and racist intolerance towards a particular ethnic minority group.
If there is one model of Laïcité that France should learn from is of its former colony Senegal. At the time of colonization, Senegal became the primary French base in West Africa. The West African nation’s secularism was heavily influenced by France’s concept of secularism with a strong sense of civil society; a tradition that has been maintained since its 1960 independence. Senegal is a vibrant democracy with 20 ethnic groups and has a predominantly Muslim population (about 94%). The Christian population represents 5% while other beliefs represent 1%. It is a country that respects and tolerates different religions and faiths. For instance, Senegal’s first President Leopold Sedar Senghor was a Catholic who ruled the country for 20 years. His successor Abdou Diouf is a Muslim married to a Christian wife. Diouf's son is a Muslim married to a Jewish wife. Abdou Diouf’s successor, Abdoulaye Wade is a Muslim married to a French Christian wife. Furthermore, Senegal recognizes both Muslim and Christian holidays as national holidays. So, religious, cultural and ethnic tolerance has been part of the DNA of Senegal.
Contrary to France, Senegal’s secularism can be described as a hybrid between the French and Anglo-Saxon models of secularism. On the one hand, the secular state maintains a separation between religious and governmental institutions, and on the other hand, it allows religious and non-religious institutions to try to influence the government, without ever threatening the nation’s peaceful coexistence among various faiths. In this context, Senegal’s form of secularism is used as a political instrument for the social control of religion while ensuring the freedom and protection of religion against persecution, abuse, and public bigotry.

Conclusion: What Secularism Should Be and Should Not Be?

Secularism should not be used as an ideology to force people to assimilate or place a ban on a person’s freedom to wear religious symbols or clothes in public, in the same way, that it is practiced in authoritarian regimes like China where religious persucution and cultural genocide is taking place, or in countries with sharia law where the State forces the wearing of hijabs. Instead, secularism should be a political principle that embraces and values all faiths, and provides the freedom of choice to all individuals.
Secularism should not be used as an excuse to perpetuate xenophobic attacks and bigotry on minorities, but instead should be used as a platform to promote tolerance of multiculturalism and diversity. Freedom of expression does not justify in any way whatsoever the attack of a person's faith or identity. Doing so is boderline hate speech that incites hatred against a particular group likely to lead to a breach of community peace.
French Aristoricrat Alexis de Tocqueville, one of the most influential political thinker behind American democracy spoke about the danger of the tyranny of the majority. The greatest danger Tocqueville saw was that public opinion would become an all-powerful force, and that the majority could tyrannize unpopular minorities and marginal individuals. Looking today, this is what is currently taking place in France again.
The conclusion is that France’s aggressive and fundamentalist version of secularism compounded with decades of stigmatization and marginalization of minorities has contributed to the radicalization of French Muslim youths, who then turn to terrorism. France should learn from the Anglo-Saxon model and Francophone models such as Senegal. Until France frees itself from denialism and takes minorities seriously in terms of cultural tolerance, ethnic identity recognition and socio-economic inclusion, France will continue to remain a country in crisis and in decline.

submitted by Majhul_101 to u/Majhul_101 [link] [comments]

2020.10.12 00:28 AbrahamKIM Permainan Among Us

Selamat sejahtera, sedar atau tidak permainan yang terkenal sekarang ini iaitu 'Among Us" mempunyai 'The Mandela Effect' tersendiri. Jika anda tidak percaya, mari kita lihat.
Umum mengetahui terdapat dua karakter di dalam permainan tersebut iaitu Crewmate dan Imposter. Ya, memang betul semua tahu karakter ini.
Perkataan Crewmate sentiasa menjadi Crewmate TETAPI kebanyakan orang salah mengenai perkataan Imposter.
Walaupun permainan ini baru sahaja popular di khalayak ramai, namun The Mandela Effect ini tidak disedari oleh semua orang.
submitted by AbrahamKIM to Ajar_Malaysia [link] [comments]

2020.10.10 07:58 weedislifeman Failed/Failing Companies Masterlist - October 2020 Update - CALLOUT FOR YOUR CANDIDATES

Failed/Failing Companies Masterlist - October 2020 Update - CALLOUT FOR YOUR CANDIDATES
I posted a much shorter list originally on March/2/2020, then updated April/16/2020, and as time marches on, the hits just keep on coming. A lot of the companies raised cash since and still qualify for the failing list now, and some have just refused to file their fins. As of now there are a total 18(?19?) failed companies (please do let me know if there are more).Keeping the failed list as short as possible, I'm adding only those that have actually failed and applied foachieved CCAA (Companies' Creditors Arrangement Act) or gone bankrupt.Regarding CANDIDATES FOR FAILURE, the main things I look at are cash balance (+any subsequent raises), accounts receivable vs payable, + cash expenses in their last quarter. If you can dig deeper and see something I don't, please let me know and I'll look at it. Often times a company from the 'ALREADY FAILED' list put out press releases promising the world up until days before they dropped the hammer on their shareholders - it all means nothing if they can't remain solvent.***Let's hear your candidates for failure (in the next 6 months) without further financing (please do your homework and check their financials on sedar).~ALEADY FAILEDOct/23/2019 - DionyMed ordered to pay $24.8M and unable, went to court to see if they qualify to be taken over to secure the debt, which they did.Dec/2/2019 - Wayland Group seeks creditor protection. Ap23/2020 - sold to the highest bidder.Dec/2/2019 - AgMedica seeks creditor protection, sale proposed Jan/17/2020.Dec/4/2019 - Eureka 93 is insolvent. Aug/28/2020 - deemed bankrupt, the paperwork needs to go through on how their parts are divided up.Feb/13/2020 - Invictus granted creditor protection.Ma20/2020 - Pure Global granted creditor protection.Ma31/2020 - CannTrust granted creditor protection under CCAA. Then received a cease trade order on the TSX April/13/2020 (due to failure to file a few slips of paper, no big deal).Ap1/2020 - James E. Wagner seek an Initial Order approving an application for creditor protection. Approved Ap13.Ap2/2020 - True Leaf seeking creditor protection under the Bankruptcy and Insolvency Act.Ap14/2020 - Ravenquest loses final HC license. They haven't filed anything since Ap27/2020. May/1/2020 - This was helpful.Ap14/2020 - Vert Infrastructure's main debt holder has security over all of the company's assets including the company's stock portfolio consisting of shares announced private issuer announced on February 27, 2019.May/14/2020 - Sunniva seeks Bankruptcy Order. Hearing scheduled June/1/2020.May/20/2020 - Green Growth Brands granted CCAA.June/5/2020 - Beleave announces its directors approve the sealing of CCAA.Jun/15/2020 - Pyxus announces filing for Chapter 11 bankruptcy.July/06/2020 - Lift & Co announces selling everything and firing everyone. "Asset-light"...winding down. Sept/17/2020 - filed for bankruptcy.July/13/2020 - Ianthus proffers a restructuring, leaving existing shareholders with 0%->2.75% ownership of the company. Oct/6/2020 - this is approved and shareholders are officially burned.July/30/2020 - FSD Pharma sells off it's cannabis assets and...this is too good not to post in full: " 'Our pharmaceutical R&D team led by Dr. Edward Brennan is actively working to submit an Investigational New Drug Application (IND) to the FDA for the use of FSD201 (ultra-micronized PEA) to treat hospitalized COVID-19 patients by down-regulating the over-expressed pro-inflammatory cytokine immune response to SARS-CoV-2 virus infection. We are hopeful to initiate the phase 2 clinical trial before the end of this year and remain cautiously optimistic that our study may improve treatment outcome for COVID-19 patients.' The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time." Jesus Christ! Not technically gone but too good not to add.Sept/16/2020 - Canopy Rivers 49% owned JV ‘PharmHouse Inc.’ obtains CCAA.~CANDIDATES FOR FAILUREAbattis - ATTAgraFlora - AGRABiome Grow - BIOCannamerica Brands - CANACore One Labs - COOLEve & Co - EVEGolden Leaf - GLHHalo Labs - HALOHarvest One - HVTIndus Holdings - INDSMym Nutraceuticals - MYMMedMen - MMENRadient - RTIRapid Dose Therapeutics - DOSETHC Biomed - THCThe Green Organic Dutchman - TGODTilt Holdings - TILTSpeakEasy - EASYSugarbud - SUGRSupreme - FIREVireo - VREOWildflower Brands - SUNZenabis - ZENA1933 Industries - TGIF
Submitted October 10, 2020 at 06:03AM
submitted by weedislifeman to weedstocksreddit [link] [comments]

2020.10.10 07:03 IvanSkavar Failed/Failing Companies Masterlist - October 2020 Update - CALLOUT FOR YOUR CANDIDATES

I posted a much shorter list originally on March/2/2020, then updated April/16/2020, and as time marches on, the hits just keep on coming. A lot of the companies raised cash since and still qualify for the failing list now, and some have just refused to file their fins. As of now there are a total 17 failed companies (please do let me know if there are more).
Keeping the failed list as short as possible, I'm adding only those that have actually failed and applied foachieved CCAA (Companies' Creditors Arrangement Act) or gone bankrupt.
Regarding CANDIDATES FOR FAILURE, I add companies that won't make it 6 months without raising cash (sometimes they just don't make it).
The main things I look at are cash balance (+any subsequent raises), accounts receivable vs payable, + cash expenses in their last quarter. If you can dig deeper and see something I don't, please let me know and I'll look at it. Often times a company from the 'ALREADY FAILED' list put out press releases promising the world up until days before they dropped the hammer on their shareholders - it all means nothing if they can't remain solvent.
Let's hear your candidates for failure (in the next 6 months) without further financing (please do your homework and check their financials on sedar).
  1. Oct/23/2019 - DionyMed ordered to pay $24.8M and unable, went to court to see if they qualify to be taken over to secure the debt, which they did.
  2. Dec/2/2019 - Wayland Group seeks creditor protection. Ap23/2020 - sold to the highest bidder.
  3. Dec/2/2019 - AgMedica seeks creditor protection, sale proposed Jan/17/2020.
  4. Dec/4/2019 - Eureka 93 is insolvent. Aug/28/2020 - deemed bankrupt, the paperwork needs to go through on how their parts are divided up.
  5. Feb/13/2020 - Invictus granted creditor protection.
  6. Ma20/2020 - Pure Global granted creditor protection.
  7. Ma31/2020 - CannTrust granted creditor protection under CCAA. Then received a cease trade order on the TSX April/13/2020 (due to failure to file a few slips of paper, no big deal).
  8. Ap1/2020 - James E. Wagner seek an Initial Order approving an application for creditor protection. Approved Ap13.
  9. Ap2/2020 - True Leaf seeking creditor protection under the Bankruptcy and Insolvency Act.
  10. Ap14/2020 - Ravenquest loses final HC license. They haven't filed anything since Ap27/2020. May/1/2020 - This was helpful.
  11. Ap14/2020 - Vert Infrastructure's main debt holder has security over all of the company's assets including the company's stock portfolio consisting of shares announced private issuer announced on February 27, 2019.
  12. May/14/2020 - Sunniva seeks Bankruptcy Order. Hearing scheduled June/1/2020.
  13. May/20/2020 - Green Growth Brands granted CCAA.
  14. June/5/2020 - Beleave announces its directors approve the sealing of CCAA.
  15. Jun/15/2020 - Pyxus announces filing for Chapter 11 bankruptcy.
  16. July/06/2020 - Lift & Co announces selling everything and firing everyone. "Asset-light"...winding down. Sept/17/2020 - filed for bankruptcy.
  17. July/13/2020 - Ianthus proffers a restructuring, leaving existing shareholders with 0%->2.75% ownership of the company. Oct/6/2020 - this is approved and shareholders are officially burned.
  18. BONUS -Not technically gone but too good not to add.
July/30/2020 - FSD Pharma sells off it's cannabis assets and...this is too good not to post in full: " 'Our pharmaceutical R&D team led by Dr. Edward Brennan is actively working to submit an Investigational New Drug Application (IND) to the FDA for the use of FSD201 (ultra-micronized PEA) to treat hospitalized COVID-19 patients by down-regulating the over-expressed pro-inflammatory cytokine immune response to SARS-CoV-2 virus infection. We are hopeful to initiate the phase 2 clinical trial before the end of this year and remain cautiously optimistic that our study may improve treatment outcome for COVID-19 patients.' The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time." Jesus Christ!
Abattis - ATT
AgraFlora - AGRA
Biome Grow - BIO
Cannamerica Brands - CANA
Core One Labs - COOL
Eve & Co - EVE
Golden Leaf - GLH
Halo Labs - HALO
Harvest One - HVT
Indus Holdings - INDS
Mym Nutraceuticals - MYM
MedMen - MMEN
Radient - RTI
Rapid Dose Therapeutics - DOSE
THC Biomed - THC
The Green Organic Dutchman - TGOD
Tilt Holdings - TILT
SpeakEasy - EASY
Sugarbud - SUGR
Supreme - FIRE
Vireo - VREO
Wildflower Brands - SUN
Zenabis - ZENA
1933 Industries - TGIF
***** EDIT *****
Candidates for Failure (Added post-OP)
Body and Mind - BAMM
Cansortium - TIMU.U
Isodiol - ISOL
North Bud - NBUD
Nutritional High - EAT
Slang - SLNG
Sproutly - SPR
Terra Tech - TRTC
Weekend Unlimited - POT
Sundial - SNDL
Ignite - BILZ
Revive - RVV
Vivo - VIVO
MJardin - MJAR
48North - NRTH
submitted by IvanSkavar to weedstocks [link] [comments]

2020.10.04 12:06 Disentibot SEDAR entregó becerros y vacas enfermas, viejas y destinadas al destajo a pequeños productores lecheros de Zacatecas...

submitted by Disentibot to mejico [link] [comments]

2020.10.04 10:10 Artech2 SEDAR entregó becerros y vacas enfermas, viejas y destinadas al destajo a pequeños productores lecheros de Zacatecas...

submitted by Artech2 to mexico [link] [comments]

2020.09.25 16:29 zxced90 $EKG(CardioComm Solutions Inc) unusual volume

Anyone know why its pumping? I can't find any news on it in sedar. Currently at .04 with 1.7mil.
submitted by zxced90 to pennystocks [link] [comments]


VANCOUVER, BRITISH COLUMBIA, CANADA (September 21, 2020) – Thoughtful Brands Inc. (CSE:TBI FSE: 1WZ1; OTCQB: PEMTF) (the “Company” or “Thoughtful Brands”), a global natural health products and eCommerce technology company, is pleased to announce that it has signed a binding term sheet to acquire (the “Proposed Acquisition”) all of the issued and outstanding shares, or all of the assets of, Kentucky-based hemp extraction company American CBD Extraction Corp. (“American CBD”). The Proposed Acquisition is expected to set the stage for Thoughtful Brands to become a fully vertically-integrated CBD company, controlling each aspect of the supply chain, including production, logistics and value chain.
Upon completion of the Proposed Acquisition, the Company will acquire an abundance of hemp biomass along with a fully equipped 41,000 square foot facility with the ability to process more than 1,200 pounds of hemp per day once licensed. Upon completion, Thoughtful Brands would also be able to utilize American CBD’s technological and scientific expertise to enhance the formulations of the Company’s various direct-to-consumer CBD brands, which include Nature’s Exclusive, Sativida and the recently acquired Golden Path and Wild Mariposa. Additionally, the Company plans to sell American CBD’s hemp biomass to support operations in Europe and to other clients worldwide.
“The term sheet with American CBD is an important milestone for the Company because it increases the likelihood of expanded margins and will allow us to launch innovative new products for which we control every step of the process,” said Thoughtful Brands CEO Ryan Hoggan. “Once we’re able to work directly with the team at American CBD and within their state-of-the-art Kentucky facility, we expect to be able to fine-tune and advance our cannabinoid product portfolio.”
Acquisition Details
The Company proposes to acquire all of the issued and outstanding share capital of, or all of the assets of, American CBD in consideration for Cdn$11,000,000, which will be satisfied through the issuance of common shares of the Company (the “Consideration Shares”). The Consideration Shares will be issued to the existing shareholders of American CBD or, in the case of an asset acquisition, directly to American CBD, at a deemed price equivalent to the lesser of (a) Cdn$0.18 per share or (b) the five-day volume-weighted average closing price of the Company’s common shares on the Canadian Securities Exchange for the period preceding closing of the Proposed Acquisition. The Consideration Shares shall be paid upfront and subject to an escrow arrangement, from which 25% of the Consideration Shares will be released on the closing date of the Proposed Acquisition, followed by an additional 25% after each subsequent 90-day period.
In addition to the Consideration Shares, a bonus of Cdn$1,000,000 will be paid to the operating team of American CBD on closing and a Cdn$2,000,000 performance milestone payment will be paid to the operating team of American CBD upon the achievement of production and cumulative online sales of over USD$1,000,000. The bonus and milestone shares will be payable in common shares of the Company based on the five-day volume weighted average closing price of the Company’s shares on the Canadian Securities Exchange immediately prior to the bonus and milestone payments becoming payable.
Closing of the Proposed Acquisition is subject to American CBD: (a) having a minimum cash balance of Cdn$2,000,000, less closing costs related to the Proposed Acquisition (which are not exceed Cdn$40,000); (b) having no debts or liabilities; and (c) having been granted a seat on the Company’s board of directors, all on the closing of the Proposed Acquisition.
The Company is at arms-length from American CBD and its shareholders. The transaction will not constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange.
Readers are cautioned that the final terms and structure for a transaction between the Company and American CBD have not yet been determined. Completion of any transaction remains subject to negotiation of definitive documentation and satisfaction of conditions set forth above, as well as customary closing conditions for a transaction of this nature. The Proposed Acquisition cannot be completed until these conditions are satisfied. The Company will provide additional information regarding the Proposed Acquisition as soon as it becomes available.
About Thoughtful Brands Inc.
Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe. Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector. Thoughtful Brands owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany, where its highly skilled team conducts clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction, while planning for future opportunities to create proprietary psilocybin products.
About American CBD Extraction Corp.
From the rich soils of Kentucky, American CBD Extraction Corp. is a Kentucky-based company that produces cannabinoid distillates and isolates, and is positioned to become a significant supplier of hemp-derived extracts. Its location in the eastern part of Kentucky, a place that has been called “The Hemp Capital of the United States,” gives American CBD the privilege to partner with the state’s most experienced farmers to source the highest quality hemp for its products. American CBD is a company founded on dedication, strong work ethic and quality, fulfilling its mission to provide consistent, high-grade and clean hemp-derived CBD oil to meet the growing demand in this evolving marketplace.
Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected]
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the completion of the Proposed Acquisition, the synergies created by the acquisition of American CBD, plans to sell hemp biomass to support its operations in Europe and to other clients worldwide, its plans to acquire additional revenue-producing natural health product brands and operations in both Europe and North America with the goal of establishing an international distribution network utilizing its eCommerce technology platform. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
submitted by MotaVenturesCorp to u/MotaVenturesCorp [link] [comments]

2020.09.10 20:22 niuz-bot Sedare digitală - ideea unui startup care a obținut o finanțare de 10 milioane de euro - [Economie][IT]

Oncomfort este un startup belgian care vine cu o metodă revoluționară prin care vrea să amelioreze durerea și anxietatea fără medicamente, printr-o așa-numită numită "sedare digitală". Firma a obținut o investiție serie A de 10 milioane de euro. Iată cum foncționează produsul digital al acestui startup.
Citeste in continuare: https://www.startupcafe.ro/smart-tech/sedare-digitala-realitate-virtuala-startup.htm
submitted by niuz-bot to niuz [link] [comments]

2020.09.09 14:41 pEot_ABC Penyakit Mental dari Perspektif Islam

1] Definisi Penyakit Mental menurut Perspektif Islam.
Penyakit Mental adalah satu Kecenderungan yang Luar Biasa untuk menyeleweng daripada sunnah Rasulullah S.A.W
2] Siapa Orang yang mempunyai Kesihatan Mental yang OK dan sihat pula?
Orang yang mempunyai Kesihatan Mental yang Baik dan Normal adalah mereka yang Tingkah Lakunya dan Pemikirannya selari dengan sunnah Rasulullah S.A.W
3] Keyword buat orang yang senasib dengan saya
Effective coping - this moment will past - if you feel Loneliness (kosong) - bersama dengan jemaah - First step to heal - Break that Endless loop - kembali kepada Allah Hati dan Fikiran - Bahagiakan diri & Orang Lain - Ubah Cara Hidup - TOTAL SURRENDER kepada Allah - Tawakkal - You need to do something - Consistent - Bersungguh-sungguh - Tolong Orang Lain supaya Allah ampunkan dosa Kita - Practice Mindfullness(sedar keadaan sekarang) - kembali berfungsi - Bagi Value to other people - Muhasabah - Menerima Teguran - jangan cepat melenting - Ready melakukan Perubahan - Kenali Diri Sendiri - dapat tahu kelebihan/kekurangan adalah kekuatan kita - Menambah baik Kehidupan - step by step renew - Kualiti Hidup - BUDAYA MENCARI ILMU & MENCARI MAKNA nak faham sesuatu - Membina hubungan yang positif dengan Allah dan manusia lain - Trust Yourself - plan - Fokus - Think - Celebrate it - never give up - Berdikari - Bersedia - Perlukan Daya Tahan yang kuat ( Resilency ) - Be Proactive - Create Meaning & Purpose in Life - Be Kind - Yakin dengan Allah - Sabar - Teruskan Kehidupan - You have that WILL POWER - Tingkatkan Ilmu - Belajar - Find Your Hidden Resources Strength - Everyone has it - Fahami konsep Aurat - Sesuatu yang sangat berharga dan harus dilindungi - Beza Kecenderungan ( Minat ) & Amalan . Keep Learning
4] Apa itu REDHA?
=>> Penerimaan Seseorang terhadap sesuatu yang terjadi dengan ikhlas/ dengan rela hati terhadap apa yang telah ditakdirkan Tuhan
=>> Penerimaan tanpa persoalan terhadap apa yang ditentukan
Kita memilih untuk REDHA dan kita akan sentiasa Bersyukur terhadap kurniaan dan Nikmat Allah beri.
5] Bincangkan antara sunnah-sunnah Rasulullah S.A.W yang perlu diamalkan oleh kami yang mengalami Penyakit Mental ini?
( Harap ada Ajarians yang sudi nak share ilmu dan bincang kat sini)
Terima Kasih, Jasa Mu di Kenang Sokmo~
submitted by pEot_ABC to Ajar_Malaysia [link] [comments]

2020.09.09 06:09 laperlabysedar467 Laperla by Sedar best services as a service apartment

Laperla by Sedar best services as a service apartment
LA Perla by Sedar offers you the best services to make your stay awesome. You’ll enjoy the best settlements and facilities such as pools, saunas and spas in the hostel at the point where you choose an extensive opportunity. If you book a similar spa meeting and a meal independently at a bar in the inn, you can pay much more for it.
Packages for holidays reserve heaps of cash. You can spend more than planned if you book anything from the accommodation to the flights alone. Individual expenses can be very high, yet a La Perla sedar service apartment has everything to do with less.

Organizations in Italy selling packages are well aware of the unique circumstances in a region. They are also aware of protected areas and dangers and can ensure that you are protected throughout your holiday. When you intend to fail all alone, you are likely to find yourself in a tough situation in dark places.
Absolute Comfort
We think comfort is the highest priority in Laperla by sedar for all. We ensure that the customer relaxes and enjoys their trial in our Service Apartment. In our furnished homes, we ensure that everything is secured.
The Full Tour
Superior Apartment:
Superior Apartment is the perfect luxurious apartments for the people who love to spend their holidays largely. There is one large double bed bedroom also one living room in which you will get one sofa bed. Private bathroom, air conditioned apartment with a flat screen TV so that every seconds of your trip is enjoyable. There is wifi, furnished living terrace and it is suitable for maximum 4 person.
One Bedroom:
The Bedroom service occupies space especially designed for those who enjoy limited but fully furnished spaces. It is air-conditioned apartment with a flat screen TV. It has one bedroom with large double bed with private bathroom. Living room with one sofa bed, free wifi and a furnished terrace.
An extraordinarily favorable travel bundles place is that you get a full tour of the city. It can be disturbing to visit all of the places of interest in an unfamiliar town or area. You may make a complete overview of the spots you need to visit, however, due to time you neglect to do as such. Holiday packages are made around major spots with the goal that guests will be given the opportunity to appreciate the full cash assistance.
La Perla by Sedar provides incredibly favorable visit bundles position so you get the absolute visit to the city. It can be disturbing to visit all of the places of interest in an unfamiliar town or area.
submitted by laperlabysedar467 to u/laperlabysedar467 [link] [comments]

2020.09.02 18:44 zxced90 ePlay(OTC:EPYFF) Successfully Gains Apple Approval For New Flagship Mobile Game

Catalyst: https://webfiles.thecse.com/ePlay_Gets_Apple_Approval_for_New_Flagship_Game_Press_Release-3.pdf?d.yxU0m314_kB9kG6HZylFHVF7KauaLT=
Financial Statements : https://webfiles.thecse.com/sedar_filings/00035728/2006151503381046.pdf
submitted by zxced90 to pennystocks [link] [comments]